Table 1 Descriptive analysis of clinicopathological and molecular characteristics
Total patients | n = 103 | |
|---|---|---|
Age | Median(range) | 49(17–75) |
Sex | Female | 27(26.2%) |
Male | 76(73.8%) | |
Smoker | Yes | 43(41.7%) |
No | 60(58.3%) | |
Alcohol | Yes | 22(21.4%) |
No | 81(78.6%) | |
Pathological grade | Undifferentiated carcinoma | 59(57.3%) |
Differentiated carcinoma | 44(42.7%) | |
cT | 1 | 13(12.6%) |
2 | 20(19.4%) | |
3 | 58(56.3%) | |
4 | 12(11.7%) | |
cN | 0 | 11(10.7%) |
1 | 27(26.2%) | |
2 | 29(28.2%) | |
3 | 36(35.0%) | |
cStage | I | 12(11.7%) |
II | 44(42.7%) | |
III | 42(40.8%) | |
IV | 5(4.9%) | |
Plasma EBV DNAa (copies/mL) | Median(Q1-Q3) | 1221(407.8- 2635.75) |
Peripheral CD4+cells%b | Median(Q1-Q3) | 33.35(27.125–41.7) |
Peripheral CD8+cells%b | Median(Q1-Q3) | 23(18.35–30.9) |
Peripheral NK cells%b | Median(Q1-Q3) | 17.85(13.5–27.9) |
Tumor-infiltrating Treg% in CD4+cells | Median(Q1-Q3) | 1.65(0.45–3.67) |
Treg Infiltration Score | Median(Q1-Q3) (×10− 4) | 0.17 (0.03–0.52) |
CD25 H Score | Median(Q1-Q3) | 7.57(3.13–10.32) |